Clinical Trial Update: Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine. [Phase 2]

View source ↗

Summary

Phase 2 trial update for a novel HPV vaccine from GlaxoSmithKline assessing immunogenicity and safety in young adult women.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection
• Papillomavirus Infection

Drugs mentioned

• GSK's novel HPV vaccine

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Papillomavirus | Phase 2 | Status: COMPLETED | Results posted: 2019-12-12